No day selected
DISCOVERY & PRECLINICAL TRACK
CLINICAL & TRANSLATIONAL UTILITY TRACK
PRECLINICAL VALIDATION FOR ALS TO HERALD A NEW ERA OF SAFER & MORE EFFECTIVE DRUGS TO THE CLINIC
GENETICALLY VALIDATED TARGETS & PRECISION THERAPEUTICS: ADVANCING ALS TREATMENT WITH UNC13A RESTORATION & STMN2 SPLICING TECHNOLOGIES IN THE CLINIC
Chair: Aarti Sharma, Director, Motor Neuron Disease, Regeneron
Chair: Olga Uspenskaya-Cadoz, Vice President, Clinical Development, Eli Lilly
No day selected
No day selected
No day selected
No day selected
No day selected
No day selected